Oncternal Therapeutics (ONCT) Stock Analysis

What Oncternal Therapeutics does

Oncternal Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating cancer treatments for diseases where current medical options are insufficient. Its clinical-stage portfolio features zilovertamab, a humanized monoclonal antibody designed to bind to ROR1 (Receptor-tyrosine kinase-like Orphan Receptor 1), and ONCT-216, a small molecule that works by inhibiting the biological activity of ETS-family transcription factor oncoproteins. Additionally, Oncternal is advancing ONCT-808, a chimeric antigen receptor T-cell (CAR-T) therapy candidate also targeting ROR1, as well as ONCT-534, a dual-action androgen receptor inhibitor aimed at treating castration-resistant prostate cancer and other cancers driven by androgen receptors. The company holds various license agreements with institutions such as the Regents of the University of California, Georgetown University, The University of Texas MD Anderson Cancer Center, Shanghai Pharmaceutical (USA) Inc., and the University of Tennessee Research Foundation. Furthermore, it engages in a research collaboration with Celularity Inc. to explore placental-derived cellular therapies that also target ROR1. Its headquarters are located in San Diego, California.

Key metrics

ETFs linked to ONCT

Broad-market and Healthcare sector ETFs an investor holding Oncternal Therapeutics is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how ONCT fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Oncternal Therapeutics?

Oncternal Therapeutics trades under the ticker ONCT on NASDAQ.

Which exchange is ONCT listed on?

ONCT is listed on NASDAQ.

What sector does Oncternal Therapeutics operate in?

Oncternal Therapeutics is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze ONCT in a portfolio?

PortView shows ONCT's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.